Takeda’s Sleep Aid Rozerem Could Avoid Controlled Substance Scheduling, Firm Says

The insomnia agent ramelteon uses a different mechanism of action than Sanofi-Aventis’ Ambien and Sepracor’s Lunesta, both of which are Schedule IV substances. Rozerem NDA is pending at FDA with a July 22 user fee date.